AVAX Technologies Announces Initiation Of Clinical Study With Autologous Ovarian Cancer Vaccine (OVax)

AVAX Technologies, Inc. (OTC Market:AVXT.OB) announces it has received FDA approval to begin enrollment into a Phase I-II clinical trial of OVax for patients with advanced, chemotherapy-refractive ovarian cancer. The study will be performed in collaboration with Cancer Treatment Centers of America, Inc (CTCA).

More: continued here

Filed under: Cancer on April 11th, 2008